Presenter's Information

Martin Bert Leon, MD

Country USA
Specialty Interventional Cardiologist
  1. The Next Chapter of Transcatheter Valve Intervention
  2. An Introduction of APOLLO Trial
  3. Contemporary Trends in Aortic Stenosis Management - Legend's Perspective
  4. The UPSTREAM Management of Aortic Stenosis
  5. TAVR Long Journey: Chain of RCTs, Guideline Changes, and Future Directions
  6. TAVR Long-Term Durability: Is It Concerned for Late-Catch Up in PARTNER-3?
  7. The Future of TAVR: A Master's Perspectives
  8. Results and Update from the Vessix RE-INFORCE Program
  9. PARTNER-3 Low-risk TAVR
  10. Sapien 3 Clinical Update
  11. PARTNER 2A - TAVR in Intermediate Risk Patients
  12. Congratulatory Remark & Keynote Lecture: "Interventional Cardiology Transitions to Structural Heart Disease"
  13. Efficacy and Safety of TAVR 2016
  14. TAVR in Lower Risk
  15. TAVR Should Replace Surgery in (Almost) ALL Aortic Stenosis Patients
  16. The Odyssey of TAVR: From Concept to Clinical Reality
  17. New TAVR Systems and Accessory Devices
  18. Interventional Cardiovascular Medicine: Past, Now and Future Perspectives
  19. New TAVI Devices
  20. Dedicated Bifurcation Stents for True Coronary Bifurcation Lesions
  21. Results of Resolute Series of Studies
  22. Update of Dedicated Bifurcation Stent
  23. TAVR Update 2012: The Year in Review
  24. TAVI Update 2012: The Year in Review
  25. Complications After TAVR: Frequency and Clinical Importance
  26. Beyond DES: Peripheral Vascular Disease, TAVI and Hypertension
  27. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
  28. PARTNER Percutaneous Transaortic Valve Implantation: What Have We Learned?
  29. Perspectives from PARTNER Trial
  30. Life after PARTNER (Inoperable and “High Risk” Cohorts): Will TAVI Therapy Change Guidelines for AS Patients?
  31. DES of the Future: Design Goals and Challenges
  32. Predicting the Future for Transcatheter Valve Therapies: New Devices and Expanded Clinical Indications
  33. Status Update and Clinical Impact of Transcatheter Aortic Valve Implantation (TAVI)
  34. My Crystal Ball - New Drug Delivery Platforms and Bioabsorbable Stents will Dominate in the Next 5-10 Years!
  35. Therapy in Evolution: Percutaneous Aortic Valve Replacement
  36. Endeavor Program Overview
  37. Long-Term Clinical Outcome of Sirolimus-Eluting Stent over 6 Years
  38. Future Perspective of Bifurcation Stenting
  39. DES Should Be Favored
  40. The Changing Landscape of DES Use Patterns: Finally Stabilizing or Still in Transition?
  41. Is Transcatheter AVR the Standard of Care for High Risk AS Patients? Summary of Worldwide Experiences
  42. ENDEAVOR IV: 2-Year FU Comparing Zotarolimus- vs. Paclitaxel-Eluting Stents
  43. Addressing the Controversy of Late DES Thrombosis
  44. DES Safety Concerns: Impact on Clinical Practice
  45. The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives
  46. The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections
  47. Overview of Percutaneous Valve Therapy
  48. A Critical Appraisal of Percutaneous Aortic Valve Therapies: Device Concepts, Clinical Outcomes, and Future Projections
  49. New DES Drug Carrier Systems: Biostable, Bioabsorbable, and No Polymers, Elution Kinetics, and Beyond!
  50. THE GREAT DEBATE : All Patients Should Receive a Drug Eluting Stent - PRO
Conference Slides
Category